A lack of finance for black investors is holding up Bidvest’s aggressive and serious attempts to dispose of its 38.5% interest in JSE-listed pharmaceutical firm Adcock Ingram, says Bidvest CEO Lindsay Ralphs. Bidvest’s preferred deal would give black investors a substantial stake in a well-established company that is set for growth, especially after Adcock’s recent acquisition of surgical and skincare products supplier Genop. Adcock’s fortunes were turned around after Bidvest bought the stake in 2014, replaced the management and restructured operations. The stake in Adcock, valued at R4.8bn at the current share price, is among assets that Bidvest wants to sell in order to focus on its core divisions. Speaking after the release of the company’s results for the year to end-June, Ralphs said Bidvest had struggled to sell the stake to black investors because of a lack of finance. "We have really attempted aggressively and seriously to dispose of [the Adcock stake] over the last two year...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.